nasopharyngeal carcinoma
Conditions
Interventions
1:docetaxel 75mg/m2 iv in day 1 +Cisplatin 75mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles
2:Cisplatin 75mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles
Sponsors
Guiyang Medical College affiliated Hospital of oncology (Cancer Hospital of Guizhou province)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary and sign the informed consent form; 2. Age 18-70 years old, male or female; 3. histologically proved to be keratinizing carcinoma or non-keratinizing carcinoma; 4. nasopharyngeal darcinoma 2010 UICC staging III-IV A, IV B; 5. measurable Primary tumors; 6. karnofsky score>=70; ECOG>=2; 7. Expected survival>=6 months; 8. Women in productive age should guarantee use contraceptives during study period; 9. Hemoglobin (HGB) >=100g/L, white blood cell (WBC) >=4*10^9/L, Platelet (PLT)>=100*10^9/L. (or white blood cell and platelet not less than our hospital's Normal lowest index); 10. liver function: Alanine amino transferase (ALAT), aspartate aminotransferase (ASAT) <1.5 times the upper limit of the normal index; total bilirubin<1.5*ULN; 11. liver function: serum creatinine<1.5*ULN; 12. do not have severe complication, such as Hypertensio, Diabetes and History of mental illness; 13. this treatment is First treatment process (do not have a H&N Radiation history; do not have a history of Concurrent chemoradiotherapy; do not have chemotherapy history in 3 months.
Exclusion criteria
Exclusion criteria: 1. Have a distant metastasis; 2. The primary focal tumors or lymph node already had a surgical treatment (except for biopsy); 3. Already had a radiotherapy for primary focal or lymph node; 4. Patient who received the the epidermal growth factor targeted therapy; 5. The primary focal had received chemoradiotherapy or immunotherapy; 6. Patient who suffered from other malignant tumor (except for cured basal cell carcinoma or carcinoma in situ of cervix); 7. Subject who have taken other drug test in 1 month; 8. Peripheral Neuropathy> level; 9. pregnant woman or Lactating Women and Women in productive age who refuse take contraception in observation period; 10. subject with a severe allergic history or idiosyncratic; 11. subject with severe pulmonary and cardiopathic disease history; 12. refuse or incapable to sign the informed consent form of participating this trial; 13. drug abuse or alcohol addicted; 14. subject with a Personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute side effects;Clinical response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;progression free survival; | — |
Countries
China
Contacts
Public ContactJing Feng
Outcome results
None listed